

The DERMABOND® Family of Topical Skin Adhesives (TSAs)

A unique and proven portfolio of products for optimized skin closure outcomes*

- #1 Best selling brand of topical skin adhesives†
- Studied in 51 randomized clinical trials (>5700 patients) designed specifically for the DERMABOND family of products*



TOPICAL SKIN ADHESIVE

Strength plus protection‡

DERMABOND® Mini Topical Skin Adhesive



Ideal for:

- Minimally invasive procedures
- Small lacerations



SKIN CLOSURE SYSTEM

Uncompromised strength plus protection to provide excellent security in wound closure§

DERMABOND® PRINEO® Skin Closure System 22 cm



Ideal for:

- Orthopedic surgeries, including
 - Total knee arthroplasty
 - Total hip arthroplasty
 - Spine surgeries

DERMABOND® ADVANCED® Topical Skin Adhesive



Ideal for:

- Open hernia repair
- Medium to large lacerations

DERMABOND® PRINEO® Skin Closure System 60 cm



Ideal for:

- Abdominoplasty
- Breast reconstruction
- Sternotomy
- Bracheoplasty

* Based on published literature in PubMed as of March 7, 2017, using only RCTs that evaluated the use of the product in a manner consistent with intended indication.†TSA Market Data, October 2017. ‡ Quinn J, Wells G, Sutcliffe T, et al. A randomized trial comparing octylcyanoacrylate tissue adhesive and sutures in the management of lacerations. JAMA.1997;277(19):1527-1530. §Keplinger 07PD048. Protocol investigation of the comparison of PRINEO with conventional wound closure techniques, May 2007.

DERMABOND® Portfolio

More clinical experience, outcomes data, and publications than any other TSA with >300 publications, including preclinical and clinical data.”

DERMABOND ADVANCED® adhesive is proven to provide **strength, protection, and consistent performance.**

Strengthens

- When used in addition to sutures, DERMABOND ADVANCED Adhesive was shown ex vivo to add 75% more strength to the wound closure than sutures alone.¹

Inhibits bacteria and provides a microbial barrier

- Demonstrated in vitro inhibition of gram-positive bacteria (MRSA and MRSE) and gram-negative bacteria (E coli).^{2*}
- Provides a flexible microbial barrier with 99% protection in vitro for 72 hours against organisms commonly responsible for surgical site infections.^{3†}
- Provides wound healing strength to maintain barrier and wound closure integrity through in vivo studies.⁴

For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference full package insert.

*Clinical significance is unknown.

**Based on published literature in PubMed as of March 7, 2017, using only RCTs that evaluated the use of the product in a manner consistent with intended indication
†Staphylococcus epidermidis, Staphylococcus aureus, Escherichia coli, Enterococcus faecium, Pseudomonas aeruginosa.

Manufacturer	ETHICON	ADVANCED MEDICAL SOLUTIONS
Products	DERMABOND ADVANCED® Topical Skin Adhesive	Cardinal Health® Liquiband® OCTYL Topical Skin Adhesive
Adhesive Formulation		
Proprietary Adhesive Formulation	Strength Flexibility Durability Consistency	Flexibility
Initiator System for Consistent Polymerization	Yes ⁵	None
Performance		
Wound Bursting Strength (3-D)	431.2 mmHg ⁶	Unknown
Tensile Strength (2-D)	10.13 lbf ⁷	6.36 lbf ⁹
Drying Time	1.6 min ⁵	2.11 min ⁹
Product Details		
Application	Single Layer ⁸	Unknown ¹⁰

The third-party trademarks used herein are trademarks of their respective owners.

References

1. Keplinger, Protocol to Determine the Strength Benefits when Adding DERMABOND® Advanced Topical Skin Adhesive to a Wound or Incision using Suture as the Primary Closure, July 2011. 2. Report prepared by Shubhangi Bhende Staff Scientist; reviewed and Approved by Dr. Martin Weisberg, Medical Director ETHICON Inc. 3. Bhende S, Rothenburger S, Spangler DJ, Dito M. In vitro assessment of microbial barrier properties of Dermabond Topical Skin Adhesive. Surg Infect (Larchmt). 2002;3(3):251-257. 4. Quinn J, Wells G, Sutcliffe T, et al. A randomized trial comparing octylcyanoacrylate tissue adhesive and sutures in the management of lacerations. JAMA. 1997;277(19):1527-1530. 5. Keplinger, 11TR053, Comparison of Setting Times of Topical Skin Adhesive Products, August 2011. 6. Pluris Report, ETH35, Biomedical Evaluation of Acute In-vivo Incision Wound Closure Strength of Topical Skin Adhesives in Swine Model, August 2011. 7. Keplinger, 09PD070, Performance Evaluation of DERMABOND® NX Topical Skin Adhesive Data report, January 2010. 8. DERMABOND ADVANCED. Instructions for Use. 9. Kumar, AST-2016-0157, Study to Evaluation Product Performance Characteristics of Exofin® and LiquiBand OCTYL Topical Skin Adhesives, November 2016. 10. Cardinal Health® Liquiband® OCTYL Topical Skin Adhesive Indication for Use

